Pharmaleads, Paris BioPark, 75013 Paris, France.
Anal Biochem. 2013 Oct 15;441(2):152-61. doi: 10.1016/j.ab.2013.06.016. Epub 2013 Jul 11.
Leukotriene A4 hydrolase (LTA4H) is a bifunctional zinc-dependent metalloprotease bearing both an epoxide hydrolase, producing the pro-inflammatory LTB4 leukotriene, and an aminopeptidase activity, whose physiological relevance has long been ignored. Distinct substrates are commonly used for each activity, although none is completely satisfactory; LTA4, substrate for the hydrolase activity, is unstable and inactivates the enzyme, whereas aminoacids β-naphthylamide and para-nitroanilide, used as aminopeptidase substrates, are poor and nonselective. Based on the three-dimensional structure of LTA4H, we describe a new, specific, and high-affinity fluorigenic substrate, PL553 [L-(4-benzoyl)phenylalanyl-β-naphthylamide], with both in vitro and in vivo applications. PL553 possesses a catalytic efficiency (k(cat)/K(m)) of 3.8±0.5×10⁴ M⁻¹ s⁻¹ using human recombinant LTA4H and a limit of detection and quantification of less than 1 to 2 ng. The PL553 assay was validated by measuring the inhibitory potency of known LTA4H inhibitors and used to characterize new specific amino-phosphinic inhibitors. The LTA4H inhibition measured with PL553 in mouse tissues, after intravenous administration of inhibitors, was also correlated with a reduction in LTB4 levels. This authenticates the assay as the first allowing the easy measurement of endogenous LTA4H activity and in vitro specific screening of new LTA4H inhibitors.
白三烯 A4 水解酶 (LTA4H) 是一种具有双重功能的锌依赖性金属蛋白酶,既具有环氧化物水解酶活性,生成促炎的 LTB4 白三烯,又具有氨肽酶活性,但其生理相关性长期以来一直被忽视。虽然每种活性都有常用的不同底物,但没有一种是完全令人满意的;LTA4 是水解酶活性的底物,但它不稳定并使酶失活,而用作氨肽酶底物的氨基酸 β-萘基酰胺和对硝基苯胺则较差且非选择性。基于 LTA4H 的三维结构,我们描述了一种新的、特异性的、高亲和力荧光底物 PL553 [L-(4-苯甲酰基)苯丙氨酰-β-萘基酰胺],具有体外和体内应用的潜力。PL553 对人重组 LTA4H 的催化效率 (kcat/Km) 为 3.8±0.5×10⁴ M⁻¹ s⁻¹,检测限和定量限均小于 1 至 2 ng。该 PL553 测定法通过测量已知 LTA4H 抑制剂的抑制效力得到验证,并用于表征新的特异性氨基膦酸抑制剂。抑制剂静脉给药后,在小鼠组织中用 PL553 测量的 LTA4H 抑制作用与 LTB4 水平的降低相关,这使该测定法成为第一个可以轻松测量内源性 LTA4H 活性和体外特异性筛选新的 LTA4H 抑制剂的方法。